22 April 2020 – update

The company has announced that its testing programme to generate Affimer reagents to help in the battle against coronavirus is ahead of schedule.  In only four weeks it has successfully generated these reagents as part of its collaboration with Cytiva (formerly GE Healthcare Life sciences) and the next step is to develop a laboratory test for a virus antigen in the next few weeks.  This is clearly very exciting news for the company and there is considerable potential for further progress in its development.  Although the shares have moved up strongly there may be further to go and we rate them as a SPECULATIVE BUY.